AI Healthcare Boom Gains Speed as Regulators and Innovators Align
The integration of artificial intelligence (AI) in healthcare is gaining momentum, with a positive ROI already seen by 90% of surveyed C-suite executives. Analysts predict that by 2035, AI could add $461 billion to the healthcare industry. Avant Technologies, Inc., along with other companies, is at the forefront of AI healthcare developments. The World Health Organization and the FDA are working on setting global standards and approving new AI technologies in healthcare. Avant Technologies' joint venture with Ainnova Tech is making significant progress in AI-powered healthcare diagnostics, aiming for FDA clearance in the U.S. market.
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC , May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion.
New AI Healthcare Tech Developments
Behind the scenes, several new AI healthcare tech developments are taking place, with updates recently coming from Avant Technologies, Inc. AVAI, Tempus AI, Inc. TEM, Tevogen Bio Holdings Inc. TVGN, GE HealthCare Technologies Inc. GEHC, and Schrödinger, Inc. SDGR.
Regulatory Initiatives and Advancements
At the regulatory level, the World Health Organization (WHO) recently announced a major global initiative to set unified standards for AI in healthcare, the US Food and Drug Administration (FDA) is working to catch up on approving new AI tech in the sector with the latest being a cardioverter defibrillator.
Avant Technologies, Inc. Innovations
Avant Technologies, Inc. AVAI, an emerging leader in AI-driven healthcare innovation, continues to accelerate its push into AI-powered healthcare diagnostics through its joint venture with Ainnova Tech, operating through Ai-nova Acquisition Corp. (AAC), a jointly controlled entity that holds global licensing rights to VisionAI and its supporting hardware.
The two companies recently announced that the FDA has officially received their request for a pre-submission meeting for VisionAI, the joint venture's flagship screening platform. This marked a pivotal moment in Avant's trajectory. VisionAI uses a combination of retinal imaging, patient vitals, and advanced algorithms to identify early warning signs of various diseases.
Future Prospects and Market Expansion
For investors tracking small-cap companies operating at the intersection of AI, diagnostics, and chronic disease management, Avant Technologies may be worth a closer look. As the FDA process moves forward and pilot programs scale, AVAI sits in a rare position—commercially active, globally licensed, and now formally in dialogue with U.S. regulators.
As AI continues to evolve from concept to clinical application, these companies are quietly shaping the future of medicine at the infrastructure level. With regulatory momentum building and real-world deployments expanding, investors may want to pay attention as this shift begins to accelerate.